CORRESPONDENCIA
Utilidad del infliximab en pioderma gangrenoso no asociado a enfermedad inflamatoria intestinal
Utility of infliximab in gangrenous pyoderma not associated with inflammatory bowel disease
Leído
187
Vecesse ha leído el artículo
113
Total PDF
74
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2026 1 | 25 | 3 | 28 |
| 2025 12 | 48 | 15 | 63 |
| 2025 11 | 0 | 7 | 7 |
| 2025 10 | 0 | 11 | 11 |
| 2025 9 | 0 | 3 | 3 |
| 2025 8 | 0 | 5 | 5 |
| 2025 7 | 0 | 2 | 2 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 2 | 2 |
| 2025 3 | 0 | 5 | 5 |
| 2025 2 | 0 | 2 | 2 |
| 2024 12 | 0 | 1 | 1 |
| 2024 11 | 0 | 2 | 2 |
| 2024 9 | 0 | 3 | 3 |
| 2024 8 | 0 | 3 | 3 |
| 2024 7 | 0 | 3 | 3 |
| 2024 6 | 0 | 2 | 2 |
| 2024 5 | 0 | 1 | 1 |
| 2024 4 | 0 | 1 | 1 |
| 2024 3 | 0 | 6 | 6 |
| 2024 2 | 0 | 2 | 2 |
| 2024 1 | 0 | 1 | 1 |
| 2023 12 | 0 | 1 | 1 |
| 2023 11 | 0 | 6 | 6 |
| 2023 10 | 0 | 7 | 7 |
| 2023 9 | 0 | 3 | 3 |
| 2023 8 | 0 | 1 | 1 |
| 2023 7 | 1 | 3 | 4 |
| 2023 6 | 0 | 6 | 6 |
| 2023 5 | 0 | 4 | 4 |
Mostrar todo
